Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Friday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 3.7 %

Shares of ENZ stock opened at $0.68 on Friday. Enzo Biochem has a 1 year low of $0.68 and a 1 year high of $1.44. The firm’s 50 day moving average is $0.93 and its 200-day moving average is $1.05.

Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Enzo Biochem Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were paid a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a dividend yield of 58.81%. The ex-dividend date was Friday, November 15th.

Institutional Trading of Enzo Biochem

Several institutional investors and hedge funds have recently made changes to their positions in ENZ. XTX Topco Ltd grew its stake in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the period. BBR Partners LLC acquired a new position in shares of Enzo Biochem during the 3rd quarter worth about $112,000. Geode Capital Management LLC increased its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after acquiring an additional 64,417 shares during the period. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.